Response to CCR-07-0070

Autoignition Behavior of the Xylene Isomers DAAD 19 - 03 - 1 - 0070 6 . AUTHOR ( S ) W 911 NF - 07 - 1 - 0522

Preignition and Autoignition Behavior of the Xylene Isomers Robert H. Natelson Nicholas P. Cernansky, Ph.D. and David L. Miller, Ph.D. The relative preignition and autoignition reactivity of the xylene isomers (o-, mand p-xylene, or 1,2-, 1,3-, and 1,4-dimethylbenzene) has been studied. The principal objectives were to determine the relative reactivity among the isomers and the key oxidation br...

CCR New

Downloa creatic cancer (PC) is a highly lethal disease with complex etiology involving both environmental netic factors. Although cigarette smoking is known to explain 25% of cases, data from recent studies sugat obesity and long-term type II diabetes are twomajor modifiable risk factors for PC. Furthermore, obed diabetes seem to affect the clinical outcome of patients with PC. Understanding th...

CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy.

The article by Rouzier and colleagues, published in the August 15, 2005, issue of Clinical Cancer Research, demonstrated that different molecular subtypes of breast cancer have different degrees of sensitivity to chemotherapy, but the extent of response to neoadjuvant therapy has a different meaning by subtype. Several molecular subtype-specific clinical trials are under way to maximize patholo...

XWH - 09 - 2 - 0070 TITLE : Corneal protection for burn patients

CCR Drug Updates

Vismodegib (GDC-0449), an orally bioavailable small-molecule inhibitor of Hedgehog signaling, was recently approved by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma that is either metastatic or locally advanced in patients who are not candidates for surgical resection or radiation. Given the absence of previously defined effective drug therapy for this disease,...